Cipla posted numbers lower than expected for 3QFY2017. The company
reported sales of Rs3,550cr v/s Rs3,737cr expected, registering a yoy growth of
15.6%, mainly aided by domestic formulations. Domestic at Rs1,408cr registered
a yoy growth of 19.1%, while exports at Rs2,239cr posted yoy growth of 13.7%.
On operating front, the EBITDA margins came in at 16.4% (v/s 16.5% expected)
v/s 12.4% in 3QFY2016. Consequently, Adj. PAT came in at Rs375cr (v/s Rs498cr
expected) v/s Rs258cr in 3QFY2016, yoy growth of 45.2%. We maintain our SELL
rating on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...